Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis
Journal of Viral Hepatitis · 2023
DOI: 10.1111/jvh.13872 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Viral Hepatitis, 2023. Verfasst von Run Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Nursing, Hangzhou Normal University, Hangzhou, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Carcinoma, Hepatocellular, Liver Neoplasms, Fatty Liver. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Hangzhou Science and Technology Bureau.
Abstract (Originalsprache)
Chronic hepatitis B (CHB) and hepatic steatosis (HS) are two prevalent chronic liver diseases in Asia. The incidence of CHB combined with HS is increasing due to the rising obesity rates. However, the impact of HS on CHB remains a topic of debate. Hereby, this meta‐analysis aims to examine the effect of HS on Asian patients with CHB. Searches were conducted on four databases to identify articles published from 2005 to 2023. The random‐effects or fixed‐effects model was used to calculate pooled odds ratios (ORs), weighted mean difference (WMD), and confidence intervals (CIs) for the included articles. Of the 15,959 records screened, 88 studies were included in the analysis of HS prevalence in Asian CHB patients with a prevalence of 36.5% (95% CI: 33.7%–39.3%). In addition, age, sex, body mass index (BMI), waist circumference (WC), alanine aminotransferase (ALT) and combined metabolic diseases have varying degrees of impact on HS in CHB patients. Furthermore, the coexistence of HS was negatively associated with the response to antiviral therapy, including hepatitis B surface antigen (HBeAg) seroconversion (OR = 0.69, 95% CI: 0.53–0.89) and ALT normalization (OR = 0.75, 95% CI: 0.61–0.92) in CHB patients after 48 weeks of treatment. Regarding disease prognosis, HS was not significantly associated with fibrosis or cirrhosis in CHB patients, while an inverse association was observed between HS and hepatocellular carcinoma (HCC) (OR = 2.93, 95% CI: 1.23–6.99). This implies that the coexistence of HS in CHB patients may exacerbate the progression of HCC, which needs to be verified by further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Nursing, Hangzhou Normal University, Hangzhou, China.
- The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
- The Department of Translational Medicine Platform, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
- Department of School of Life Sciences, Zhejiang University of Traditional Chinese Medicine, Hangzhou, China.
- School of Nursing, Henan University of Chinese Medicine, Zhengzhou, China.
- Department of Teaching, Hangzhou Normal University, Hangzhou, China.
ORCID-Profile: Jie Li, Junping Shi
Förderung
- Natural Science Foundation of Shandong Province
- Hangzhou Science and Technology Bureau
Zitieren
APA
Zhou, R., Yang, L., Zhang, B., Gu, Y., Kong, T., Zhang, W., Sun, L., Liu, C., Kong, N., Li, J., & Shi, J. (2023). Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13872
Vancouver
Zhou R, Yang L, Zhang B, Gu Y, Kong T, Zhang W, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis. Journal of Viral Hepatitis. 2023. doi:10.1111/jvh.13872
BibTeX
@article{Zhou2023,
author = {Zhou, Run and Yang, Luping and Zhang, Binbin and Gu, Yunpeng and Kong, Tingting and Zhang, Wei and Sun, Lei and Liu, Chunlan and Kong, Ningjia and Li, Jie and Shi, Junping},
title = {Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: A systematic review and meta‐analysis},
journal = {Journal of Viral Hepatitis},
year = {2023},
doi = {10.1111/jvh.13872}
}
EUVIMED